TCH与TAC新辅助化疗在HER-2过表达乳腺癌中的疗效观察

Efficacy observation of TCH/TAC neoadjuvant chemotherapy in treatment of HER-2 over-expressing breast cancer

    摘要
  • 摘要:
      目的  观察TCH与TAC新辅助化疗方案在HER-2过表达乳腺癌的临床疗效。
      方法  收集深圳市第二人民医院甲乳外科自2008年5月至2012年9月收治的64例HER-2过表达的乳腺癌患者，随机分为两组：TCH组39例，采用曲妥珠单抗联合多西他赛及卡铂治疗方案；TAC组25例，采用多西他赛、表阿霉素及环磷酰胺治疗方案。新辅助化疗6个周期后进行疗效对比。
      结果  TCH与TAC两组患者总有效率（OR）分别为94.9%（37/39）和72.0%（18/25），差异有统计学意义（P < 0.05）；病理完全缓解率（pCR）分别为69.2%（27/39）和32.0%（8/25），差异有统计学意义（P < 0.05）；两组患者在心功能障碍、骨髓抑制及肝功能损害等不良反应方面疗效均无显著性差异。
      结论  在HER-2过表达乳腺癌的新辅助化疗中，多西他赛及卡铂联合曲妥珠单抗疗效良好，病理完全缓解率高。

     

    Abstract:
      Objective  To observe the efficacy of neo-adjuvant chemotherapy with TCH and TAC regimens on the treatment of breast cancer caused by HER-2 over-expression.
      Methods  A total of 64 HER-2 over-expression breast cancer patients were randomly divided into two groups. In the group treated with the TCH regimen, 39 patients underwent the Trastuzumab treatment combined with Docetaxel and Carboplatin. In the group treated with the TAC regimen, 25 patients underwent therapy using Docetaxel, Epirubicin, and Cyclophosphamide. Neo-adjuvant chemotherapy was continued for six cycles until a comparison of the therapeutic effects was made.
      Results  The overall responses (OR) of patients in the two groups-TCG and TAC-were 94.9% (37/39) and 72% (18/25), respectively, P < 0.05. The pathologic complete responses (pCR) were 69.2% (27/39) and 32.0% (8/25), respectively, P < 0.05. No significant differences were observed between the two groups in terms of adverse reactions, such as cardiac dysfunction, bone marrow suppression, and liver function impairment.
      Conclusion  During the treatment of HER-2 over-expressing breast cancer patients with neoadjuvant chemotherapy, Trastuzumab combined with Docetaxel and Carboplatin showed a favorable efficacy and a high pCR rate.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回